We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma (SLAT)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 17, 2009
Last Update Posted: April 17, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Spanish Lung Cancer Group
This is a pharmacogenic, prospective, and multicenter study in patients with advanced lung adenocarcinoma.

Condition Intervention
Non-Small Cell Lung Cancer Drug: Docetaxel Drug: Docetaxel-Cisplatin Drug: Gemcitabine-Cisplatin Drug: Erlotinib

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Tratamiento Individualizado en función de Las Mutaciones en EGFR y Del Nivel de expresión de BRCA1 en Pacientes Con Adenocarcinoma de pulmón Avanzado

Resource links provided by NLM:

Further study details as provided by Spanish Lung Cancer Group:

Primary Outcome Measures:
  • Tumoral Response (RECIST criteria)

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: 2 years ]

Enrollment: 153
Study Start Date: June 2005
Study Completion Date: November 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Docetaxel
Docetaxel 75 mg/day 1 x 4 cycles
Drug: Docetaxel-Cisplatin
Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
Drug: Gemcitabine-Cisplatin

Cisplatin 75 mg/ day 1 x 4 cycles

Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles

Drug: Erlotinib
Erlotinib 150 mg/day x 21 days

Detailed Description:
Pharmacogenomic study, prospective, multicenter. Individualized treatment based on EGFR mutations and level of BRCA1 expression in patients with advanced lung adenocarcinoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients age 18 years or more.
  • Histologically confirmed diagnosis of non-small-cell lung carcinoma.(and indifferentiated and BAC histology).

    • Only patients with advanced disease, defined as stage IV or IIIB with/without pleural effusion, will be included.
    • Tumor sample available.
    • A measurable lesion, as defined by RECIST criteria.
    • Karnofsky score 60% or more (ECOG < 2).
    • Patients should not have received previous treatment with chemotherapy or other agents for disseminated disease. Chemotherapy is allowed if the initial diagnosis of the patient is limited disease and the patient has received adjuvant or neoadjuvant treatment.
  • Patients with cerebral disease are permitted, without any time limitations after holocranial irradiation or complementary antiedema treatment.
  • Patients with hepatical, renal and hematology normality values.
  • Patients should sign an informed consent form before inclusion in the study that specifies that the clinical trial treatment entails consent for the analysis of biological samples of tumor and blood.
  • Patients of childbearing age of either sex must use effective contraceptive methods (barrier methods or other birth control methods) before entering the study and while participating in the study.
  • Patients must be available for clinical follow-up..

Exclusion Criteria:

  • Patients who have received an investigational medicinal product in the 21 days before inclusion in the study or antiEGFR receptor agent.
  • Severe comorbidity.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00883480

Ico-Hospital Universitarios Germans Trias I Pujol
Badalona, Barcelona, Spain, 08916
Hospital Carlos Haya
Málaga, Spain
Sponsors and Collaborators
Spanish Lung Cancer Group
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Rafael Rosell, Spanish Lung Cancer Group
ClinicalTrials.gov Identifier: NCT00883480     History of Changes
Other Study ID Numbers: SLAT
First Submitted: December 22, 2008
First Posted: April 17, 2009
Last Update Posted: April 17, 2009
Last Verified: April 2009

Keywords provided by Spanish Lung Cancer Group:

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Erlotinib Hydrochloride
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Tubulin Modulators
Antimitotic Agents